A Phase III Open-Label, Multicentre Trial of Maintenance Therapy with Avelumab (MSB0010718C) Versus Continuation of First-Line Chemotherapy in Subjects with Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of Stomach, or of the Gastro-Esophageal Junction